Curative Cash from 2010 to 2026
| CUBT Stock | USD 0.01 0.0007 11.29% |
Cash | First Reported 2013-03-31 | Previous Quarter 19.5 K | Current Value 218.3 K | Quarterly Volatility 245.1 K |
Check Curative Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Curative Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 111.3 K, Interest Expense of 1.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 55.01, Dividend Yield of 0.0 or Days Sales Outstanding of 267. Curative financial statements analysis is a perfect complement when working with Curative Biotechnology Valuation or Volatility modules.
Curative | Cash | Build AI portfolio with Curative Stock |
The evolution of Cash for Curative Biotechnology provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Curative Biotechnology compares to historical norms and industry peers.
Latest Curative Biotechnology's Cash Growth Pattern
Below is the plot of the Cash of Curative Biotechnology over the last few years. Cash refers to the most liquid asset of Curative Biotechnology, which is listed under current asset account on Curative Biotechnology balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Curative Biotechnology customers. The amounts must be unrestricted with restricted cash listed in a different Curative Biotechnology account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Curative Biotechnology's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Curative Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Curative Cash Regression Statistics
| Arithmetic Mean | 60,725 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 266.94 | |
| Mean Deviation | 83,461 | |
| Median | 3,676 | |
| Standard Deviation | 162,099 | |
| Sample Variance | 26.3B | |
| Range | 670.3K | |
| R-Value | 0.24 | |
| Mean Square Error | 26.4B | |
| R-Squared | 0.06 | |
| Significance | 0.35 | |
| Slope | 7,770 | |
| Total Sum of Squares | 420.4B |
Curative Cash History
Other Fundumenentals of Curative Biotechnology
| Cash And Short Term Investments | ||
| Change In Cash | ||
| Total Cashflows From Investing Activities | ||
| Total Cash From Operating Activities |
Curative Biotechnology Cash component correlations
Click cells to compare fundamentals
About Curative Biotechnology Financial Statements
Curative Biotechnology shareholders use historical fundamental indicators, such as Cash, to determine how well the company is positioned to perform in the future. Although Curative Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Curative Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Curative Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash | 22.5 K | 21.3 K | |
| Cash And Short Term Investments | 22.5 K | 21.3 K | |
| Change In Cash | -33.2 K | -31.5 K | |
| Total Cashflows From Investing Activities | -12.6 K | -13.3 K | |
| Total Cash From Operating Activities | -920.5 K | -874.4 K | |
| Total Cash From Financing Activities | 1.1 M | 1.2 M | |
| Other Cashflows From Investing Activities | -12.6 K | -12 K | |
| End Period Cash Flow | 22.5 K | 21.3 K | |
| Free Cash Flow | -920.5 K | -874.4 K | |
| Begin Period Cash Flow | 64.9 K | 87.9 K | |
| Other Cashflows From Financing Activities | 98.5 K | 59.9 K | |
| Other Non Cash Items | 1.9 M | 2 M | |
| Free Cash Flow Yield | (0.10) | (0.10) | |
| Capex To Operating Cash Flow | (0.03) | (0.03) | |
| EV To Operating Cash Flow | (14.58) | (15.31) | |
| EV To Free Cash Flow | (14.58) | (15.31) | |
| Price To Operating Cash Flows Ratio | (13.07) | (13.72) | |
| Price To Free Cash Flows Ratio | (13.07) | (13.72) | |
| Cash Conversion Cycle | -14.7 K | -15.4 K | |
| Operating Cash Flow Sales Ratio | (0.61) | (0.58) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.18 | 1.42 | |
| Cash Flow Coverage Ratios | (0.86) | (0.82) | |
| Price Cash Flow Ratio | (13.07) | (13.72) | |
| Cash Flow To Debt Ratio | (0.86) | (0.82) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.